NCT06894095 Dongzong Cardiovascular Bio-imaging Registry Study
| NCT ID | NCT06894095 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinling Hospital, China |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2023-05-24 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2023-05-24 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The DAILY project is a large-scale, multicenter, prospective initiative designed to establish a comprehensive bio-imaging database that integrates multidimensional data, including living environments, psychosocial and cognitive assessments, advanced lung and cardiovascular imaging, multi-omics profiles, clinical medication and surgical records, and health outcomes. Leveraging this extensive, multiscale dataset, the project aims to elucidate the intricate interplay between genetic biology and environmental factors in driving downstream biological alterations, thereby shaping lung and cardiovascular structural and functional phenotypes, and ultimately influencing the onset and progression of cardiovascular diseases (CVD). Through a systematic exploration and understanding of this complex network, the project seeks to identify critical intervention points and develop innovative strategies for the prevention and management of CVD.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years * Coronary CT angiography performed * Informed consent acquired Exclusion Criteria: * Unable to complete the follow-up * Serious chronic kidney disease (eGFR\< 30 ml/min/1.73 m2) * Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3 times the upper limit of normal) * Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc. * Suspected or known infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), and Treponema pallidum (syphilis), etc.
Contact & Investigator
Longjiang Zhang, MD
PRINCIPAL INVESTIGATOR
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
Frequently Asked Questions
Who can join the NCT06894095 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894095 currently recruiting?
Yes, NCT06894095 is actively recruiting participants. Contact the research team at kevinzhlj@163.com for enrollment information.
Where is the NCT06894095 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06894095 clinical trial?
NCT06894095 is sponsored by Jinling Hospital, China. The principal investigator is Longjiang Zhang, MD at Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University. The trial plans to enroll 50,000 participants.